Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

ABSTRACT: MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

PROVIDER: PRJNA591123 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2.

Project description:BackgroundLipid accumulation has been highlighted in cancer development and progression, but the exact mechanism remains unclear in renal cell carcinoma (RCC). MicroRNAs (miRNAs) have been confirmed to participate in the pathological processes of cancers, including tumour occurrence and inhibition. However, the role and mechanism of miR-765 have not been elucidated in clear cell renal cell carcinoma (ccRCC).MethodsUsing The Cancer Genome Atlas (TCGA) database and qRT-PCR, we investigated differences in miR-765 and proteolipid protein 2 (PLP2) expression, as well as their clinical relevance. To investigate the function of miR-765 and PLP2 in ccRCC, we performed in vitro and in vivo experiments to explore their biological functions in ccRCC.FindingsIn this study, we showed that miR-765 was upregulated in the plasma of ccRCC patients after tumour resection. Consistently, ccRCC tissues had low expression of miR-765 when compared with corresponding non-cancerous tissues. Overexpression of miR-765 suppressed cell proliferation and metastasis in vitro and in vivo. Mechanistic studies demonstrated that PLP2 was a direct target gene of miR-765. PLP2 was highly expressed in ccRCC tissues, and high PLP2 levels were positively correlated with higher tumour stage and grade and poor prognosis. PLP2 expression was negatively correlated with the miR-765 level in patient samples. We further showed that PLP2 restrained the cell metastasis and proliferation induced by miR-765 and reduced the lipid-eliminating effects of miR-765 in renal cancer cells.InterpretationOur findings suggest that miR-765 may function as a tumour suppressor and eliminate lipids in clear cell renal cell carcinoma by targeting PLP2.FundingThis work was funded the grants from the National Natural Scientific Foundation of China (Grant No. 81672528, 81672524, 81602218, 31741032, 81902588).

| S-EPMC6948168 | biostudies-literature

MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

Project description:MicroRNAs (miRNAs) expression profiles are widely investigated in the major cancers, but their expression in patients plasmas of cancers have not yet to be fully elucidated. We investigated expression profiles of miRNAs in patients preoperative/postoperative plasmas of clear cell renal cell carcinomas (ccRCCs) by using a miRNAs microarray platform which covers a total of 1,523 human miRNAs.

2020-01-13 | GSE140835 | GEO

Zea mays cultivar:RSQ-765

Project description:Zea mays RSQ-765 Transcriptome

| PRJNA493354 | ENA

Desulfosporosinus orientis DSM 765

Project description:Desulfosporosinus orientis DSM 765 genome sequencing project

| PRJNA66191 | ENA

Vibrio parahaemolyticus strain:765

Project description:Vibrio parahaemolyticus 765 genome sequencing and assembly

| PRJNA324105 | ENA

Melissococcus plutonius strain:765-6B

Project description:Melissococcus plutonius strain:765-6B Genome sequencing and assembly

| PRJNA263539 | ENA

Transcriptional profiling of rats treated with VX-765 and Anakinra

Project description:Various studies showed a significant production/release of IL-1 beta following status epilepticus (SE) and during epileptogenesis. We studied the role of this cytokine in the epileptogenic process by blocking its production and downstream effects in vivo in a model of acquired epilepsy following SE induction. We used a pharmacological strategy consisting of the administration of two drugs, namely VX-765 and Anakinra, which selectively block the biosynthesis and the receptor type 1 of this cytokine, respectively.

2013-12-10 | E-MTAB-1567 | biostudies-arrayexpress

Mesorhizobium loti strain:UFLA 01-765

Project description:Mesorhizobium loti strain:UFLA 01-765 Genome sequencing and assembly

| PRJNA306524 | ENA

Cohesin loss eliminates all loop domains

Project description:Cohesin loss eliminates all loop domains

| PRJNA412386 | ENA

miR-765 induces angiogenesis by inhibiting dipeptidyl peptidase 4 and increasing fibroblast growth factor 2

Project description:Given that extracellular vesicles (EVs) secreted from stem cells contain angiogenic microRNAs (miRNAs), these EVs show equivalent angiogenic therapeutic effect to cell transplantation. This study aimed to identify the angiogenic miRNAs from several miRNAs involved in EVs secreted from stem cells. In human dental pulp stem cells (hDPSCs) under hypoxic culture, vascular endothelial growth factor (VEGF) involved in EVs increased. We hypothesized that angiogenic miRNAs increase in EVs that are secreted from hDPSCs under hypoxic culture compared with those under normoxic culture. In the first screening, the expression levels of miRNAs involved in EVs that were secreted from hDPSCs cultured under hypoxic and normoxic conditions were analyzed using miRNA array. In the second screening, 12 miRNAs were individually involved in EVs, and the growth of human aortic endothelial cells was assayed. In the third screening, miRNA-encapsulated EVs were injected in BALB/c mouse hindlimb ischemia model, followed by angiogenesis evaluation by blood flow analysis. Results showed that miR-765 is an angiogenic miRNA, targeting the 3′ untranslated region of dipeptidyl peptidase 4 (DPP4) and upregulating fibroblast growth factor 2 (FGF2) in vitro and in vivo. In conclusion, as an angiogenesis mechanism, miR-765 increased FGF2 expression levels by inhibiting DPP4.

2024-05-08 | GSE232178 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data